Taisin Scientific Announces Board Approval of Consolidated Financial Report for Q2 2026

1. Date of Board Reporting or Board Resolution: 2026/08/04 2. Audit Committee Approval Date: 2026/08/04 3. Financial Reporting Period: 2026/01/01 ~ 2026/06/30 4. Cumulative Operating Revenue from January 1 to Reporting Date (in thousands): 6,918,905 5. Cumulative Operating Profit (Loss) from January 1 to Reporting Date (in thousands): 276,561 6. Cumulative Operating Income (Loss) from January 1 to Reporting Date (in thousands): (9,722) 7. Cumulative Pre-Tax Net Profit (Loss) from January 1 to Reporting Date (in thousands): (21,773) 8. Cumulative Net Profit (Loss) for the Period from January 1 to Reporting Date (in thousands): (20,274) 9. Cumulative Net Profit (Loss) Attributable to Owners of Parent from January 1 to Reporting Date (in thousands): (20,274) 10. Cumulative Basic Earnings (Loss) Per Share from January 1 to Reporting Date (in NT$): (0.05) 11. Total Assets at Reporting Date (in thousands): 51,283,543 12. Total Liabilities at Reporting Date (in thousands): 26,988,973 13. Equity Attributable to Owners of Parent at Reporting Date (in thousands): 24,294,570 14. Other Matters to be Disclosed: None